March 21 (Reuters) - Sinclair Pharma Plc * FY sales growth of 51% at £37.8 million, (2015: £25.0 million, 18 months £45.5 million) * FY gross profit increased 56% to £26.7 million (2015: £17.1 million, 18 months £31.8 million) * FY adjusted ebitda* loss narrowed to £6.1 million (2015: £8.0 million, 18 months £15.4 million) * Trading in Q1 2017 in line with management expectations * Looking ahead, board expects Sinclair to be adjusted EBITDA positive in 2017 - CEO Source text for Eikon: Further company coverage:
Sinclair Pharma has posted a financial year sales growth of 51%, to £37.8m ($47.2m), compared to 2015 numbers, which stood at £25m. The company said it had achieved this by increasing its production capacity from 550,000 pills per annum in 2014 to 1.1m tablets and capsules last year. The company's board expects 2017 earnings before interest, taxes, depreciation and amortisation to be positive.